14176-10-4
Chemical Structure
Cetiedil
- CAS No.: 14176-10-4
- Formula:C20H31NO2S
- Molecular Weight:349.53
IUPAC Name: 2-(azepan-1-yl)ethyl 2-cyclohexyl-2-(thiophen-3-yl)acetate
InChIKey: MMNICIJVQJJHHF-UHFFFAOYSA-N
SMILES: O=C(OCCN1CCCCCC1)C(C2=CSC=C2)C3CCCCC3
Biological Activity: Cetiedil is a vasodilator and potassium channel blocker with anti-sickle cell and analgesic activities. Cetiedil increases cyclic adenosine monophosphate levels, relaxes vascular smooth muscle, and blocks the action of Bradykinin (HY-P0206). Cetiedil inhibits platelet aggregation, reduces plasma fibrinogen concentration and blood viscosity, suppresses sickling of sickle red blood cells and improves their filterability, and decreases irreversible sickle cells. Cetiedil binds to calmodulin, inhibits Ca2+-dependent potassium permeability of erythrocyte membranes, increases sodium permeability of erythrocytes, and regulates polymorphonuclear leukocyte function. Cetiedil can be used in research related to intermittent claudication, arteriosclerosis obliterans, diabetic arteriosclerosis, Raynaud's disease, angina pectoris, and sickle cell anemia[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cetiedil | Cetiedil is a vasodilator and potassium channel blocker with anti-sickle cell and analgesic activities. Cetiedil increases cyclic adenosine monophosphate levels, relaxes vascular smooth muscle, and blocks the action of Bradykinin (HY-P0206). Cetiedil inhibits platelet aggregation, reduces plasma fibrinogen concentration and blood viscosity, suppresses sickling of sickle red blood cells and improves their filterability, and decreases irreversible sickle cells. Cetiedil binds to calmodulin, inhibits Ca2+-dependent potassium permeability of erythrocyte membranes, increases sodium permeability of erythrocytes, and regulates polymorphonuclear leukocyte function. Cetiedil can be used in research related to intermittent claudication, arteriosclerosis obliterans, diabetic arteriosclerosis, Raynaud's disease, angina pectoris, and sickle cell anemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Benjamin LJ, et al. Cetiedil: its potential usefulness in sickle cell disease. Blood. 1980 Feb;55(2):265-70. [Content Brief]
- [2]. Agre P, et al. Bepridil and cetiedil. Vasodilators which inhibit Ca2+-dependent calmodulin interactions with erythrocyte membranes. J Clin Invest. 1984 Sep;74(3):812-20. [Content Brief]
- [3]. Berkowitz LR, et al. Effect of cetiedil, an in vitro antisickling agent, on erythrocyte membrane cation permeability. J Clin Invest. 1981 Nov;68(5):1215-20. [Content Brief]
- [4]. Levine SN, et al. Cetiedil inhibition of calmodulin-stimulated enzyme activity. Biochem Pharmacol. 1984 Feb 15;33(4):581-4. [Content Brief]
Keywords
